Current Practice Patterns for Treatment of Retinopathy of Prematurity
| Autor: | Caroline R. Baumal, Kirstin L. Tawse, Karen W. Jeng-Miller |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pediatrics
medicine.medical_specialty genetic structures Demographics VEGF receptors MEDLINE Angiogenesis Inhibitors Gestational Age Subspecialty 03 medical and health sciences 0302 clinical medicine Surveys and Questionnaires medicine Humans Initial treatment Retinopathy of Prematurity 030212 general & internal medicine Practice Patterns Physicians' Laser Coagulation biology business.industry Infant Newborn Retinopathy of prematurity medicine.disease eye diseases Bevacizumab Current practice Intravitreal Injections 030221 ophthalmology & optometry biology.protein Pediatric ophthalmology sense organs business |
| Zdroj: | Ophthalmic Surgery, Lasers and Imaging Retina. 47:491-495 |
| ISSN: | 2325-8179 2325-8160 |
| Popis: | To evaluate current practice patterns for the treatment of retinopathy of prematurity (ROP) and characterize factors influencing clinical decisions, a database of all ophthalmologists subspecializing in pediatrics and retina was compiled from membership directories of subspecialty societies and academic institutions in the United States. A web-based survey was emailed to these subspecialists to obtain information regarding demographics, treatment practices, and preferences in hypothetical clinical scenarios. From 2,977 retina and pediatric ophthalmology subspecialists surveyed, 302 self-reported as treating ROP, of whom 56% reported having performed intra-vitreal anti-VEGF injection for ROP. Anti-vascular endothelial growth factor (VEGF) injection was the initial treatment for posterior type 1 high risk ROP preferred by the majority of surveyed ROP treaters, whereas 66% reported uncertainty regarding long-term side effects as the largest barrier to its use. Geographic practice location was associated with anti-VEGF use ( P = .019). Anti-VEGF injection as ROP therapy was preferred in some scenarios in our sample. Concerns regarding potential anti-VEGF side effects warrant further investigation. Clinical Implications: Intravitreal anti-VEGF injection was chosen as the initial therapeutic option by the majority of ROP treatment providers for posterior type 1 ROP in this survey that assessed treatment preferences for a range of clinical scenarios. Uncertainty regarding long-term side effects was the largest reported barrier to use of anti-VEGF for ROP treatment. [ Ophthalmic Surg Lasers Imaging Retina . 2016;47:491–495.] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|